skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Biosimilars represent both vast opportunities and uncharted threats across pharma. The expert analysts at Pharma Intelligence continually monitor the emerging Biosimilars market with up-to-date analysis of global market access and trial strategies, information regarding biosimilars for autoimmune diseases, exclusive Physician and KOL insights, and cutting-edge ROI analysis. Strategically align yourself with the trajectory of Biosimilars for 2017, and effectively plan for a profitable future.

Stay ahead of the Biosimilars market with materials from Datamonitor Healthcare and Trialtrove, part of the Informa Pharma Intelligence suite of products. Whether you’re developing a strategy to defend profits against newly emerging Biosimilars, or seeking to accurately assess new opportunities in Biosimilars investment, we have the intelligence you need to accurately inform your business decisions.

Infographic: Biosimilar Portfolio and Pipeline Progress

A snapshot view of aspects of the developing Biosimilar market, it covers information including:

· Which companies faced the most biosimilar competition last year

· Leading companies for biosimilar launches, 2016

· Number of biosimilars in active development by phase, 2011-2016

· Biosimilar deal volume

· Key biosimilar alliances by potential value


Download the  Sample Report

Uncover the market issues and trends affecting Biosimilars. The full report contains vital information for Biosimilars approved for the US market, and contains information like:

· An overview of the Biosimilars market

· Table: FDA Guidance on Biosimilars Published to Date

· Substitution and naming policy controversies

· Data and market exclusivity of biologics

White Paper: The Coming of Age of Biosimilars in Autoimmune and Inflammatory Diseases

Biosimilars for autoimmune drugs, including humira, remicade, etanercept, rituximab and others, have been in clinical development for several years. This essential report covers:

· The impacts of faster clinical development timelines promises

· The global availability of the innovator drugs

· Updates on current development programs

· The challenges and successes of Biosimilars for autoimmune 

Download the Infographic

 

 

 

 

 

 

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: